Compare RVSN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | LPCN |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 19.1M |
| IPO Year | N/A | 2011 |
| Metric | RVSN | LPCN |
|---|---|---|
| Price | $6.30 | $2.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.9K | ★ 182.9K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $1.81 |
| 52 Week High | $9.39 | $12.37 |
| Indicator | RVSN | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 30.62 | 32.44 |
| Support Level | $0.32 | $2.20 |
| Resistance Level | $8.96 | $2.50 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.11 | 0.16 |
| Stochastic Oscillator | 10.94 | 21.64 |
Rail Vision Ltd is a development-stage technology company that is engaged in the design, development, and assembly of railway detection systems designed to solve the challenges in railway operational safety, efficiency, and predictive maintenance. Its railway detection systems include different types of cameras, including optics, visible light spectrum cameras (video), and thermal cameras that transmit data to a ruggedized onboard computer which is designed to be suitable for the rough environment of a train's locomotive. It has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.